APAC LS & HC Report 2023
Asia Pacific Life Sciences & Healthcare Report 2023


Asia Pacific Life Sciences & Healthcare Report 2023

Tracking the investible opportunity and M&A potential within the life sciences and healthcare space in APAC

Download the report
In partnership with FinanceAsia, we studied the most significant recent trends in the life sciences and healthcare sector to arrive at an understanding of the factors that could power or inhibit its growth in 2023 and beyond. Besides this critical historic context, we have provided a view into what the future looks like for life sciences and healthcare via bespoke research involving key stakeholders. We surveyed* investors and advisors that are actively engaged in the space, as well as senior executives at life sciences and healthcare companies to obtain informed insights on the opportunities and challenges that come with investments in the sector.

Key findings:
  • Despite a challenging 2022, the life sciences and healthcare sector is expected to bounce back in 2023 with robust growth as governments and businesses alike continue to focus on health and wellbeing in response to increased consumer demand for personalized care. Most survey respondents demonstrate optimism about the sector’s growth prospects and investors’ interest in life sciences and healthcare.
  • APAC will receive increased investor focus as factors such as its region’s ageing population and increasing pressures on public healthcare systems create more demand. Rising health consumerism and digital innovations will be major influencing factors on adoption and supply of life sciences and healthcare products and services.
  • Though APAC’s life sciences and healthcare industry has traditionally lagged counterparts in North America and Europe, strong fundamentals such as its rising middle class and digitally savvy populations provide ripe opportunities for innovators and healthcare providers.
  • The most active verticals expected to draw a bulk of investments and M&A are medical technology (medtech) and devices (25.0%), biotechnology (19.4%), pharmaceutical research and development (R&D) (19.4%) and healthcare solutions (19.4%).
To read the survey results and learn more about the sector’s future potential, download the DFIN Asia Pacific Life Sciences & Healthcare Report 2023.

*A survey was conducted between December 2022 and March 2023 among 68 verified respondents who are investors, advisors and senior executives engaged or working in the life sciences and healthcare space. The survey covered respondents across the APAC region including Australia, China, Hong Kong, India, Indonesia, Japan, Korea, Malaysia, the Philippines, Singapore, and Thailand. In addition to the results which were analyzed and summarized in this report, we also referred to many recent reports and articles on significant developments within the life sciences and healthcare space to provide a comprehensive picture of the sector and insights into its potential.

Download now to learn more.

Fill out the form below to get the new Life Sciences & Healthcare Report.